丰原药业
(000153)
| 流通市值：27.63亿 | | | 总市值：28.35亿 |
| 流通股本：4.53亿 | | | 总股本：4.65亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 940,757,024.36 | 4,284,620,583.14 | 3,261,422,843.25 | 2,307,876,468.11 |
| 营业收入 | 940,757,024.36 | 4,284,620,583.14 | 3,261,422,843.25 | 2,307,876,468.11 |
| 二、营业总成本 | 900,028,700.48 | 4,129,106,104.24 | 3,112,687,590.78 | 2,188,816,635.08 |
| 营业成本 | 734,073,801.33 | 3,352,142,795.05 | 2,525,865,523.95 | 1,768,934,954.47 |
| 税金及附加 | 7,883,763.79 | 33,962,006.19 | 26,103,971.1 | 17,729,270.56 |
| 销售费用 | 97,653,829.08 | 472,290,589.77 | 384,733,267.46 | 284,701,959.93 |
| 管理费用 | 35,681,496.94 | 178,623,419.99 | 114,105,171.23 | 76,776,982.48 |
| 研发费用 | 17,238,043.8 | 63,134,710.39 | 40,361,583.34 | 26,360,784.48 |
| 财务费用 | 7,497,765.54 | 28,952,582.85 | 21,518,073.7 | 14,312,683.16 |
| 其中:利息费用 | 8,336,459.95 | 30,361,057.66 | 23,037,925.31 | 15,015,703.81 |
| 其中:利息收入 | 981,353.78 | 2,184,232.81 | 1,904,128.83 | 914,211.45 |
| 加:公允价值变动收益 | -4,344,385.24 | -5,283,485.49 | -9,916,334.26 | -18,160,043.69 |
| 加:投资收益 | -600 | 9,220,093.88 | 9,902,752.75 | 4,009,134.25 |
| 资产处置收益 | - | -1,613,956.1 | -1,135,848.39 | -1,135,848.39 |
| 资产减值损失(新) | -1,462,911.9 | -5,177,068.1 | -1,279,211.87 | -1,305,840.82 |
| 信用减值损失(新) | -1,604,496.49 | -9,773,840.64 | -4,563,621.79 | -3,555,321.76 |
| 其他收益 | 10,544,434.21 | 62,199,931.31 | 41,454,662.17 | 35,808,574.79 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 43,860,364.46 | 205,086,153.76 | 183,197,651.08 | 134,720,487.41 |
| 加:营业外收入 | 477,603.93 | 4,451,189.5 | 2,964,679.37 | 872,021.54 |
| 减:营业外支出 | 216,490.96 | 818,656.79 | 279,359.74 | 47,224.6 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 44,121,477.43 | 208,718,686.47 | 185,882,970.71 | 135,545,284.35 |
| 减:所得税费用 | 6,793,777.44 | 51,067,779.73 | 40,791,878.17 | 36,767,346.95 |
| 六、净利润 | 37,327,699.99 | 157,650,906.74 | 145,091,092.54 | 98,777,937.4 |
| 持续经营净利润 | 37,327,699.99 | 157,650,906.74 | 145,091,092.54 | 98,777,937.4 |
| 归属于母公司股东的净利润 | 38,020,772.3 | 160,834,825.11 | 147,302,850.89 | 100,212,492.64 |
| 少数股东损益 | -693,072.31 | -3,183,918.37 | -2,211,758.35 | -1,434,555.24 |
| (一)基本每股收益 | 0.08 | 0.35 | 0.32 | 0.22 |
| (二)稀释每股收益 | 0.08 | 0.35 | 0.32 | 0.22 |
| 八、其他综合收益 | 5,223,904.42 | 5,136,856.98 | -808,596.84 | 1,745,139.81 |
| 归属于母公司股东的其他综合收益 | 5,168,521.94 | 4,966,506.25 | -963,258.21 | 1,607,776.64 |
| 九、综合收益总额 | 42,551,604.41 | 162,787,763.72 | 144,282,495.7 | 100,523,077.21 |
| 归属于母公司股东的综合收益总额 | 43,189,294.24 | 165,801,331.36 | 146,339,592.68 | 101,820,269.28 |
| 归属于少数股东的综合收益总额 | -637,689.83 | -3,013,567.64 | -2,057,096.98 | -1,297,192.07 |
| 公告日期 | 2025-04-25 | 2025-04-11 | 2024-10-31 | 2024-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |